Danaher Corporation $DHR Shares Purchased by Pinnacle Wealth Planning Services Inc.

Pinnacle Wealth Planning Services Inc. boosted its stake in Danaher Corporation (NYSE:DHR) by 13.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,296 shares of the conglomerate’s stock after acquiring an additional 402 shares during the period. Pinnacle Wealth Planning Services Inc.’s holdings in Danaher were worth $651,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. MGO One Seven LLC boosted its stake in Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock worth $5,145,000 after purchasing an additional 20,813 shares during the period. Chicago Capital LLC raised its holdings in shares of Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after buying an additional 1,391 shares during the last quarter. UniSuper Management Pty Ltd boosted its stake in shares of Danaher by 1.6% during the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after buying an additional 2,667 shares during the period. Nvwm LLC grew its holdings in shares of Danaher by 20.4% during the second quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after buying an additional 1,204 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. increased its position in Danaher by 1.9% in the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock valued at $63,787,000 after acquiring an additional 6,136 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of recent research reports. Evercore ISI increased their price objective on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Bank of America decreased their price target on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Robert W. Baird set a $247.00 price objective on shares of Danaher in a research report on Wednesday, October 22nd. Cowen restated a “buy” rating on shares of Danaher in a research report on Wednesday, October 22nd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research note on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Price Performance

Danaher stock opened at $225.75 on Wednesday. The company has a market cap of $159.46 billion, a P/E ratio of 46.55, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The business has a fifty day moving average of $206.70 and a two-hundred day moving average of $201.47. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the firm posted $1.71 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 29,728 shares of company stock worth $6,448,990. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.